These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

860 related items for PubMed ID: 18174868

  • 21. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
    Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M.
    J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
    [Abstract] [Full Text] [Related]

  • 22. Corticosteroid treatment of refractory Kawasaki disease.
    Lang BA, Yeung RS, Oen KG, Malleson PN, Huber AM, Riley M, Ebbeson R, Ramsey SE, Laxer RM, Silverman ED, McCrindle BW, Ratnapalan S, Feldman BM.
    J Rheumatol; 2006 Apr; 33(4):803-9. PubMed ID: 16583481
    [Abstract] [Full Text] [Related]

  • 23. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 24. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
    Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R.
    J Paediatr Child Health; 2004 Dec; 40(9-10):524-9. PubMed ID: 15367145
    [Abstract] [Full Text] [Related]

  • 25. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
    Kubota M, Usami I, Yamakawa M, Tomita Y, Haruta T.
    J Paediatr Child Health; 2008 Jun; 44(6):359-62. PubMed ID: 18476929
    [Abstract] [Full Text] [Related]

  • 26. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
    Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
    [Abstract] [Full Text] [Related]

  • 27. Late intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Muta H, Ishii M, Yashiro M, Uehara R, Nakamura Y.
    Pediatrics; 2012 Feb; 129(2):e291-7. PubMed ID: 22250032
    [Abstract] [Full Text] [Related]

  • 28. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Wang CL, Wu YT, Lee CJ, Liu HC, Huang LT, Yang KD.
    J Pediatr; 2002 Oct; 141(4):560-5. PubMed ID: 12378198
    [Abstract] [Full Text] [Related]

  • 29. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
    Kuwabara M, Yashiro M, Ae R, Yanagawa H, Nakamura Y.
    Int J Cardiol; 2018 Oct 15; 269():334-338. PubMed ID: 30049499
    [Abstract] [Full Text] [Related]

  • 30. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
    J Microbiol Immunol Infect; 2007 Oct 15; 40(5):395-400. PubMed ID: 17932598
    [Abstract] [Full Text] [Related]

  • 31. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
    Lee TJ, Kim KH, Chun JK, Kim DS.
    Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
    [Abstract] [Full Text] [Related]

  • 32. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T.
    J Pediatr; 2004 Apr 31; 144(4):496-9. PubMed ID: 15069399
    [Abstract] [Full Text] [Related]

  • 33. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
    Weng KP, Hsieh KS, Huang SH, Ou SF, Ma CY, Ho TY, Lai CR, Ger LP.
    Kaohsiung J Med Sci; 2012 Jan 31; 28(1):23-9. PubMed ID: 22226058
    [Abstract] [Full Text] [Related]

  • 34. A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease.
    Arj-ong S, Chotivitayatarakorn P, Lertsapcharoen P, Khongphatthanayothin A, Thisyakorn C.
    J Med Assoc Thai; 2003 Jun 31; 86 Suppl 2():S179-88. PubMed ID: 12929987
    [Abstract] [Full Text] [Related]

  • 35. A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission.
    Nomura Y, Arata M, Koriyama C, Masuda K, Morita Y, Hazeki D, Ueno K, Eguchi T, Kawano Y.
    J Pediatr; 2010 May 31; 156(5):786-91. PubMed ID: 20097355
    [Abstract] [Full Text] [Related]

  • 36. [Clinical features of recurrent Kawasaki disease in 20 children].
    Zou LX, Gong FQ.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct 31; 10(5):617-9. PubMed ID: 18947484
    [Abstract] [Full Text] [Related]

  • 37. [Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease].
    Du ZD, Di Z, Du JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF.
    Zhonghua Yi Xue Za Zhi; 2009 Jul 14; 89(26):1841-3. PubMed ID: 19953930
    [Abstract] [Full Text] [Related]

  • 38. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 14; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 39. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
    Pediatrics; 2005 Dec 14; 116(6):e760-6. PubMed ID: 16322132
    [Abstract] [Full Text] [Related]

  • 40. Comparison of factors associated with coronary artery dilation only versus coronary artery aneurysms in patients with Kawasaki disease.
    Sabharwal T, Manlhiot C, Benseler SM, Tyrrell PN, Chahal N, Yeung RS, McCrindle BW.
    Am J Cardiol; 2009 Dec 15; 104(12):1743-7. PubMed ID: 19962487
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.